GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Buyback Yield %

KLTO (Klotho Neurosciences) Buyback Yield % : -4.07 (As of Apr. 23, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Klotho Neurosciences's current buyback yield was -4.07%.


Klotho Neurosciences Buyback Yield % Historical Data

The historical data trend for Klotho Neurosciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Buyback Yield % Chart

Klotho Neurosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Buyback Yield %
- - - -1.33

Klotho Neurosciences Quarterly Data
Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.13 -0.36 -1.33

Competitive Comparison of Klotho Neurosciences's Buyback Yield %

For the Biotechnology subindustry, Klotho Neurosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Klotho Neurosciences's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Klotho Neurosciences's Buyback Yield % falls into.


;
;

Klotho Neurosciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Klotho Neurosciences's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.12 + 0.295) / 13.134285
=-1.33%

Klotho Neurosciences's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.12 + 0.295) / 13.134285
=-1.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Klotho Neurosciences Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Klotho Neurosciences Business Description

Traded in Other Exchanges
N/A
Address
13576 Walnut Street, Suite A, Omaha, NE, USA, 68144
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.